Research developments of adjuvant therapies for hepatocellular carcinoma after resection / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology
;
(6): 233-237, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-745289
ABSTRACT
Hepatocellular carcinoma (HCC) is a common malignancy with high rate of morbidity and mortality.Liver resection is the most effective curative treatment,yet subsequent recurrence and death are common,with 5-year overall survival rate remaining about 50% and 5-year postoperative recurrence reaching as high as 60%-70% reported by previous publications.Therefore,it is essential to identify the optimal adjuvant therapy for patients with unfavorable prognostic factors to decrease the postoperative recurrence or metastasis,thereby to deliver the promise of improved outcomes.However,there is no consensus about it and several treatment options were under investigation,including transcatheter arterial chemoembolization (TACE),radiotherapy,targeted therapy,and other treatments.Here,we review studies on the role of adjuvant therapies,to provide evidences for further research and clinical practice.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo prognóstico
Idioma:
Chinês
Revista:
Chinese Journal of Radiation Oncology
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS